DualityBio Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Public

  • Employees
  • 266

Employees

  • Stock Symbol
  • 09606

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $13.03
  • (As of Friday Closing)

DualityBio General Information

Description

Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.

Contact Information

Website
www.dualitybiologics.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Full floor, 11th floor, tower a, Datang International Plaza
  • China Construction Engineering Group, No. 868 Yinghua Road, Pudong New Area
  • Shanghai, 201204
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
HKG
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Full floor, 11th floor, tower a, Datang International Plaza
  • China Construction Engineering Group, No. 868 Yinghua Road, Pudong New Area
  • Shanghai, 201204
  • China
+86 021

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DualityBio Stock Performance

As of 13-Nov-2026, DualityBio’s stock price is $13.03. Its current market cap is $1.19B with 91M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$13.03 $13.86 $12.24 - $48.33 $1.19B 91M 1.06M -$0.04

DualityBio Financials Summary

As of 30-Jun-2026, DualityBio has a trailing 12-month revenue of $120M.

In Thousands,
USD 		TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,633,523 2,880,859
Revenue 120,350 257,496 270,541 252,519
EBITDA (219,113) (372,756) (146,965) (32,729)
Net Income (205,579) (360,828) (146,393) (50,533)
Total Assets 516,139 556,387 286,328 211,595
Total Debt 55,850 21,407 725 750
Public Fundamental Data provided by Morningstar, Inc. disclaimer

DualityBio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore DualityBio‘s full profile, request access.

Request a free trial

DualityBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DualityBio Investments (1)

DualityBio’s most recent deal was a Joint Venture with DB-1303 (BioNTech / DualityBio). The deal was made on 01-Apr-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
DB-1303 (BioNTech / DualityBio) 01-Apr-2023 Joint Venture Drug Discovery
To view DualityBio’s complete investments history, request access »

DualityBio ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

29.23 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view DualityBio’s complete esg history, request access »

DualityBio FAQs

  • When was DualityBio founded?

    DualityBio was founded in 2019.

  • Where is DualityBio headquartered?

    DualityBio is headquartered in Shanghai, China.

  • What is the size of DualityBio?

    DualityBio has 266 total employees.

  • What industry is DualityBio in?

    DualityBio’s primary industry is Drug Discovery.

  • Is DualityBio a private or public company?

    DualityBio is a Public company.

  • What is DualityBio’s stock symbol?

    The ticker symbol for DualityBio is 09606.

  • What is the current stock price of DualityBio?

    As of 13-Nov-2026 the stock price of DualityBio is $13.03.

  • What is the current market cap of DualityBio?

    The current market capitalization of DualityBio is $1.19B.

  • What is DualityBio’s current revenue?

    The trailing twelve month revenue for DualityBio is $120M.

  • What is DualityBio’s annual earnings per share (EPS)?

    DualityBio’s EPS for 12 months was -$0.04.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process